Biocon Limited

Biocon Limited

Biocon Limited has secured the earliest licensed launch dates for its biosimilar Pebrilzo (bPertuzumab) following a global patent settlement with Genentech. The settlement enables Biocon to launch Pebrilzo in Q1 of 2027 in the European Union and UK, Q3 of 2028 in the U.S., and in 2026-2028 in other Rest of the World (RoW) countries or earlier in certain circumstances.

Biocon Limited

Biocon Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, confirming dematerialization of securities and listing on stock exchanges.

Biocon Limited

Biocon Limited has received an Order-In-Original from the Office of the Assistant Commissioner (ST) regarding a Goods and Service tax demand of Rs. 1,85,28,762/-, interest of Rs. 1,17,59,033/- and penalty of Rs. 18,52,476/- for non-submission of Special Economic Zone (SEZ) endorsement documents, improper claim of Input Service Distribution credits, and input tax reversed under temporary reversal instead of permanent reversal.

Biocon Limited

Biocon Limited has informed the Exchange about Grant of Employee Stock Options under Biocon Unity Long Term Incentive Plan 2026.

Biocon Limited

Biocon Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015.

Biocon Limited

Biocon Limited has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA), UK for its new drug product fill finish unit for Semglee (insulin glargine) at its insulin manufacturing facility in Malaysia.

Biocon Limited

Biocon Limited's wholly-owned subsidiary, Biocon Biologics Limited, has received a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) for its Pertuzumab biosimilar, Pebrilzo, for the treatment of HER2-positive breast cancer in Europe.

Biocon Limited

Biocon Limited has informed the Exchange about the remittance of final dividend for the FY 2025-26, with a final dividend of ₹ 0.50 per equity share of face value ₹ 5/- approved by the Members of the Company at the 48th Annual General Meeting.

Biocon Limited

Biocon Limited has informed the Exchange about a scheduled meeting with analysts/institutional investors on September 11, 2026, in Mumbai.

Biocon Limited

Biocon Limited has secured a 10-year supply contract for Pertuzumab in Brazil, a monoclonal antibody used in the treatment of HER2-positive breast cancer, through a partnership with Bahiafarma and Bionovis under Brazil's Productive Development Partnership (PDP) program.

Biocon Limited

Biocon Limited has informed the Exchange about the schedule of meetings with analysts/institutional investors, as per Regulation 30(6) of the SEBI Listing Regulations. The meetings will be held on September 4, 2026, at Nomura Asian Credit Corporate Day 2026 Group Virtual. The company will not disclose any Unpublished Price Sensitive Information (UPSI) during the meetings.

Biocon Limited

Biocon Limited has informed the Exchange about the remittance of final dividend for the FY 2025-26, with a dividend of ₹ 0.50 per equity share.

Biocon Limited

Biocon Limited has received marketing approval for its pegfilgrastim biosimilar from Japan's Ministry of Health, Labour and Welfare (MHLW). This approval strengthens Biocon's portfolio of biosimilar products in Japan and reaffirms the company's commitment to increasing patient access to high-quality and affordable medications globally.

Biocon Limited

Biocon Limited's US subsidiary has received US FDA approval for Yesintek (ustekinumab-kfce) single-dose prefilled autoinjector, expanding its immunology product portfolio in the US.

Biocon Limited

Biocon Limited has informed the Exchange about a scheduled meeting with analysts/institutional investors at the 22nd Annual Global Investor Conference in Mumbai on August 17, 2026.

Biocon Limited

Biocon Limited has informed the Exchange about the transcript of its Q1 FY27 Earnings Conference Call, which was held on August 06, 2026. The transcript is available on the company's website.

Biocon Limited

Biocon Limited has submitted the Exchange a copy of the Srutinizers report of the 48th Annual General Meeting held on August 06, 2026, and informed the Exchange regarding voting results.

Biocon Limited

Biocon Limited has informed the Exchange about the schedule of meetings with analysts/institutional investors, as per SEBI Listing Regulations.

Biocon Limited

Biocon Limited has informed the Exchange about the schedule of meetings with analysts/institutional investors, as per SEBI Listing Regulations.

Biocon Limited

Biocon Limited has announced its unaudited financial results for the quarter ended June 30, 2026, with revenue from operations at Rs. 43,360 million and profit attributable to shareholders at Rs. 1,411 million.